Initiating levodopa therapy for Parkinson's disease

Movement Disorders

Volumn 29, Issue 3, 2014, Pages 430-430

  Olanow, C Warren ^a,b   Kieburtz, Karl ^c   Stocchi, Fabrizio ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

DYSKINESIA; HUMAN; LETTER; LOW DRUG DOSE; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; UNIFIED PARKINSON DISEASE RATING SCALE; DYSKINESIA, DRUG-INDUCED; FEMALE; MALE;

ANTIPARKINSON AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE;

EID: 84896126224     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25805     Document Type: Letter

References (4)

1. Rajput AH. Factors predictive of development of levodopa induced dyskinesia and wearing-off in Parkinson's disease [letter]. Mov Disord 2014;29:428.
2. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
3. Fahn S, Oakes D, Shoulson I, et al; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
4. Olanow CW, Kieburtz K, Rascol O, et al; Stalevo Reduction in Dyskinesia Evaluation ion Parkinson's Disease (STRIDE-PD) Investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013;28:1064-1071.